1. Home
  2. ANAB vs DV Comparison

ANAB vs DV Comparison

Compare ANAB & DV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ANAB

AnaptysBio Inc.

HOLD

Current Price

$55.75

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo DoubleVerify Holdings Inc.

DV

DoubleVerify Holdings Inc.

HOLD

Current Price

$9.53

Market Cap

1.6B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANAB
DV
Founded
2005
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.6B
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
ANAB
DV
Price
$55.75
$9.53
Analyst Decision
Buy
Buy
Analyst Count
11
17
Target Price
$74.64
$16.18
AVG Volume (30 Days)
587.2K
2.8M
Earning Date
03-03-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
91.02
N/A
EPS
N/A
0.30
Revenue
$234,603,000.00
$748,291,000.00
Revenue This Year
N/A
$12.68
Revenue Next Year
$33.49
$9.75
P/E Ratio
N/A
$31.65
Revenue Growth
157.01
13.92
52 Week Low
$15.40
$7.61
52 Week High
$68.39
$16.82

Technical Indicators

Market Signals
Indicator
ANAB
DV
Relative Strength Index (RSI) 42.55 40.60
Support Level $52.68 $8.95
Resistance Level $57.70 $11.60
Average True Range (ATR) 4.06 0.35
MACD -1.35 -0.08
Stochastic Oscillator 8.37 26.82

Price Performance

Historical Comparison
ANAB
DV

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About DV DoubleVerify Holdings Inc.

DoubleVerify Holdings Inc is a media effectiveness platform that leverages artificial intelligence (AI) to drive superior outcomes for international brands by creating transparent ad transactions. Its solutions provide unbiased data analytics to improve the effectiveness, quality and return on advertising investments. DV Authentic Ad is its proprietary metric measuring whether an ad was delivered in a brand suitable environment, fully viewable, by a real person and in geography, while DV Pinnacle delivers these metrics in real time. The Company's solutions are integrated across programmatic platforms, social media channels and digital publishers, and are accredited by the Media Rating Council for digital ad measurement. It operates in the United States and international markets.

Share on Social Networks: